Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/BOR.0000000000000732 http://scihub22266oqcxt.onion/10.1097/BOR.0000000000000732 32744823!ä!32744823 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Opin+Rheumatol 2020 ; 32 (5): 429-433 Nephropedia Template TP {{tp|p=32744823|t=2020. COVID-19: a primer for the rheumatologist: management of patients and care settings |pdf=|usr=}}{{32744823}} gab.com Text COVID-19: a primer for the rheumatologist: management of patients and care settings JO: Curr Opin Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=32744823 #FOAvip PURPOSE OF REVIEW: There are currently many unanswered questions surrounding the management of patients with immune-mediated inflammatory diseases during the COVID-19 pandemic and several 'rapid' guidelines have been released, although are subject to be updated and changed in the near future. The purpose of this review is to discuss the approach to management of patients with immune-mediated diseases during the COVID-19 pandemic. RECENT FINDINGS: At present, there is little evidence to suggest an increased risk of COVID-19 infection or its complications in patients with immune-mediated diseases or associated with conventional or biologic disease modifying antirheumatic drugs; however, glucocorticoid use does appear to have negative associations. SUMMARY: Currently, conventional and biologic disease modifying antirheumatic drugs can be continued in the absence of SARS-CoV-2 exposure. In the case of exposure, with the exception of hydroxyhcloroquine and sulfasalazine, immunosuppression should be held for 2 weeks. Our recommendations and the guidelines we discuss here are based on C-level recommendations but help provide a framework for how to counsel our patients during this pandemic. Twit Text FOAVip COVID-19: a primer for the rheumatologist: management of patients and care settings ????Curr Opin Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=32744823 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32744823 #FOAvip English Wikipedia <ref>{{Cite pmid|32744823}}</ref> COVID-19: a primer for the rheumatologist: management of patients and care settings #MMPMID32744823 Calabrese C; Lehman B Curr Opin Rheumatol 2020[Sep]; 32 (5): 429-433 PMID32744823show ga PURPOSE OF REVIEW: There are currently many unanswered questions surrounding the management of patients with immune-mediated inflammatory diseases during the COVID-19 pandemic and several 'rapid' guidelines have been released, although are subject to be updated and changed in the near future. The purpose of this review is to discuss the approach to management of patients with immune-mediated diseases during the COVID-19 pandemic. RECENT FINDINGS: At present, there is little evidence to suggest an increased risk of COVID-19 infection or its complications in patients with immune-mediated diseases or associated with conventional or biologic disease modifying antirheumatic drugs; however, glucocorticoid use does appear to have negative associations. SUMMARY: Currently, conventional and biologic disease modifying antirheumatic drugs can be continued in the absence of SARS-CoV-2 exposure. In the case of exposure, with the exception of hydroxyhcloroquine and sulfasalazine, immunosuppression should be held for 2 weeks. Our recommendations and the guidelines we discuss here are based on C-level recommendations but help provide a framework for how to counsel our patients during this pandemic. |*Betacoronavirus[MESH] |*Clinical Competence[MESH] |Antirheumatic Agents/*therapeutic use[MESH] |COVID-19[MESH] |Comorbidity[MESH] |Coronavirus Infections/*epidemiology[MESH] |Humans[MESH] |Immunosuppression Therapy/*methods[MESH] |Pandemics[MESH] |Pneumonia, Viral/*epidemiology[MESH] |Rheumatic Diseases/complications/*drug therapy/epidemiology[MESH] |Rheumatologists/*standards[MESH]COVID-19: a primer for the rheumatologist: management of patients and (epmc).pdf DeepDyve Pubget Overpricing